New hope for liver cancer patients: drug combo trial launches
Disease control
Recruiting now
This study tests a new drug, WGI-0301, combined with sorafenib in 60 adults with advanced liver cancer that cannot be removed by surgery and has not responded to prior immunotherapy. The goal is to find the safest dose and see if the combination can shrink tumors. Participants mu…
Phase: PHASE2 • Sponsor: Zhejiang Haichang Biotech Co., Ltd. • Aim: Disease control
Last updated May 08, 2026 12:03 UTC